Praxis Collaborates with Remagine Labs to Develop Drug Patch
Praxis Precision and Remagine Labs announced a research collaboration and license agreement to develop an iontophoretic transdermal patch for the delivery of ulixacaltamide, Praxis's highly selective T-type calcium channel inhibitor in development for essential tremor. Under the agreement, Praxis and Remagine will collaborate to apply Remagine's platform, designed for precise, multi-day active transdermal dosing, to ulixacaltamide, complementing Praxis's oral program. Praxis has also made an equity investment in Remagine Labs.
